BOOK
Vasoactive Intestinal Peptides Pituitary Adenylate Cyclase Activating Polypeptide And Related Regulatory Peptides: From Molecular Biology To Clinical Applications
(1994)
Additional Information
Book Details
Abstract
This volume tells of the quest for cosmology as seen by some of the finest cosmologists in the world. It starts with “Galaxy Formation from Start to Finish” and ends with “The First Supermassive Black Holes in the Universe,” exploring in between the grand themes of galaxies, the early universe, expansion of the universe, dark matter and dark energy. This up-to-date collection of review articles offers a general introduction to cosmology and is intended for all probing into the profound questions on where we came from and where we are going.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Half Title page | i | ||
| Title page\r | iii | ||
| Copyright\r | iv | ||
| Preface | v | ||
| Organizing Committee | vii | ||
| Contents\r | ix | ||
| I. BIOSYNTHESIS AND STRUCTURE-FUNCTION | 1 | ||
| 1. Biosynthesis and processing of PACAP and characterization of its receptors\r | 3 | ||
| 2. Expression of a VIP-Beta galactosidase transgene | 24 | ||
| 3. PACAP related peptide (PRP) is expressed in the rat brain | 27 | ||
| 4. Recombinant production of VIP and polyVIP analogs\r | 36 | ||
| 5. Decreased VIP catabolism by endopeptidase 24.11 blockade is associated with inhibition of VIP secretion\r | 47 | ||
| 6. Total synthesis and some properties of human glicentin | 51 | ||
| 7. Miniglucagon-generating endopeptidase: A novel enzyme which liberates a biologically active fragment from glucagon\r | 62 | ||
| 8. Immunoradiometric assay for GLP-l(7-37)\r | 69 | ||
| 9. Interactions between biotinyl -epsilon -aminocaproylated fonns of vasoactive intestinal polypeptide (VIP) and VIP antisera \r | 76 | ||
| 10. Rational design of bis-pyrrol containing pseudopeptide with agonistic properties for VIP receptor sites\r | 85 | ||
| 11. Structure activity studies on VIP, ll. Synthesis of analogues modified at positions Arg12, Arg14,-Lys15, Met17 and Lys20-Lys21, including a potent VIP/PHM-hybrid | 89 | ||
| 12. Design, synthesis and biological actions of PACAP-related peptides based on sttuctures from NMR studies\r | 93 | ||
| II. RECEPTORS\r | 99 | ||
| 1. G-Proteins and membrane transduction: A new model\r | 101 | ||
| 2. Molecular cloning and functional expression of the pituitary adenylate cyclase activating polypeptide(PACAP) type I receptor\r | 113 | ||
| 3. The PACAP type I receptor: Cloning and functional diversity of six splice variants\r | 124 | ||
| 4. Cloning of a common VIP-PACAP receptor from human intestine\r | 129 | ||
| 5. Splicing of the rat type I PACAP receptor\r | 143 | ||
| 6. Purification of the porcine brain PACAP-l receptor by directed ligand affinity chromatography\r | 152 | ||
| 7. Characterization of the VIP receptor/effector system in human liver\r | 162 | ||
| 8. Helodermin-affinity receptors on human neuroblastoma NB-OK-l cells\r | 173 | ||
| 9. Pharmacological characterization of a new type of VIP receptor on the melanoma-derived cell line IGR37 | 179 | ||
| 10. Molecular characterization and signal transduction by the glucagon -like peptide-1 receptor | 187 | ||
| 11. A cDNA construct allowing the expression of the rat hepatic glucagon receptors\r | 194 | ||
| 12. Functional characterization and differential expression of a human adenosine A3 receptor and rat somatostatin receptor subtypes\r | 203 | ||
| 13. Ontogenic study of the VIP receptor/effector system in rat prostate\r | 219 | ||
| 14. Dynamics of partially deglycosylated VIP receptor\r | 227 | ||
| III. NEURONAL FUNCTIONS\r | 237 | ||
| 1. VIP neurons in the cerebral cortex: Promiscuous cells with homeostatic functions | 239 | ||
| 2. Met-enkephalin and vasoactive intestinal polypeptide modulate guanine nucleotide regulated proteins in the caudate nucleus of the rat\r | 254 | ||
| 3. PACAP and VIP immunoreactivities in the hypothalamic magnocellular neurons in rat and cat Colocalization study with oxytocin\r | 259 | ||
| 4. The VIP neuronal system of the suprachiasmatic nucleus of the hypothalamus, with special reference to afferent and efferent synaptic connectivity\r | 272 | ||
| 5. PACAP-like immunoreactivity and binding sites in putative nociceptive pathways of the spinal cord and brainstem | 283 | ||
| 6. Influence of chronic hypoxia on VIP-like immunoreactivity in peripheral structures and discrete brainstem nuclei of rats\r | 293 | ||
| 7. PACAP receptors in the rat cerebellum during development | 298 | ||
| 8. PACAP is expressed in sensory neurons and suppresses spinal nociceptive reflexes | 304 | ||
| 9. PACAP in the rabbit eye: Vascular effects and distribution of receptors, coupled to adenylate cyclase | 310 | ||
| 10. Neuronal VIP: From gene to sexual behavior, memory and clinical application\r | 314 | ||
| 11. Glucagon-like peptide -1(7-36)amide and the brain: studies on receptor and neurotransmitters | 325 | ||
| IV. ENDOCRINE AND NEUROENDOCRINE FUNCTIONS | 333 | ||
| 1. Sudden and sequential activation of adenyl cyclase, immediate early and tyrosine hydroxylase genes in primary chromaffin cell cultures transiently exposed to PACAP\r | 335 | ||
| 2. Distibution and neuroendocrine actions of pituitary adenylate cyclase-activating polypeptide(pACAP) in amphibians\r | 342 | ||
| 3. Regulation of VIP expression in the rat anterior pituitary | 355 | ||
| 4. Increased expression of VIP mRNA and prepro-VIP derived peptides | 368 | ||
| 5. Effect of frog pituitary adenylate cyclase-activating polypeptide (p ACAP) on amphibian pituitary cells | 376 | ||
| 6. CRH and PACAP regulate early immediate and neuropeptide genes in pituitary cells and neurons\r | 381 | ||
| 7. VIP- and PACAP-containing nerve fibers in the parathyroid glands of cat, dog and sheep\r | 394 | ||
| 8. VIP and preproVIP 22-79 in the human ovary. Localization and in vitro effects | 397 | ||
| 9. Helodermin. calcitonin and CGRP in endocrine cells of the developing rat lung.\r | 401 | ||
| 10. GLP-l (7-36) amide and insulin secretion | 405 | ||
| 11. Pituitary adenylate cyclase activating polypeptide (PACAP-38) stimulates insulin release on isolated islets of Langerbans and its action is not antagonized by DB 133-50\r | 418 | ||
| V. CLINICAL RELEVANCE\r | 425 | ||
| 1. Potential role of vasoactive intestinal polypeptide and related peptides in starvation and endurance exercise | 427 | ||
| 2. Effects of PACAP and VIP on the isolated rat heart\r | 433 | ||
| 3. Hormonal and cardiovascular effects of vasoactive intestinal peptide\r | 440 | ||
| 4. Pituitary adenylate cyclase activating pepticfes are endothelium-independent dilators of human and porcine coronary arteries\r | 450 | ||
| 5. The protective effect of vasoactive intestinal peptide (VIP) and naloxone combination of rat's kidney exposed to severe haemorrhage and reperfusion\r | 459 | ||
| 6. PACAP: in vitro effects on rabbit vascular and non-vascular smooth muscle\r | 466 | ||
| 7. The effect of PACAP on gastrointestinal blood flow in conscious dogs\r | 470 | ||
| 8. PACAP (1-15) partially antagonizes PACAP-evoked chloride secretion in isolated guinea-pig distal colon\r | 474 | ||
| 9. Effects of vasoactive intestinal peptide in experimental colitis: colonic motility\r | 481 | ||
| 10. Effect of ethanol treatment upon the vasoactive intestinal polypeptide (VIP)receptor/effector system in rat seminal vesicle\r | 491 | ||
| 11. Suppression of pancreatic glucagon by intestinal proglucagon-derived peptides: A novel feedback loop?\r | 500 | ||
| 12. The effect of streptozotocin induced diabetes on the PACAP and VIP systems in rat prostatic membranes | 504 | ||
| VI. CELLULAR PROLIFERATION | 513 | ||
| 1. The role of GRF receptor in pituitary cell proliferation | 515 | ||
| 2. Use of the multiple trans-activation properties of SV 40 large T and small t antigens to understand regulation of growth responsive genes | 527 | ||
| 3. PACAP (6-38) is a PACAP type I receptor antagonist on small cell lung cancer cells\r | 537 | ||
| 4. Inhibition of proliferation of human small-cell lung carcinoma by vasoactive intestinal peptide and helodermin: Role of cyclic AMP | 545 | ||
| 5. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by the human SSTR somatostatin receptor subtype expressed in NIH 3T3 cells | 554 | ||
| 6. Cell signaling pathway involved in PACAP-induces AR4-2J cell proliferation\r | 565 | ||
| 7. Pharmacological characterization of VIP/PACAP type II receptors in normal and immortalized rat fetal intestinal epithelial cells\r | 568 | ||
| 8. Effects of PACAP38, PACAP27 and VIP on human neuroblastoma NB-OK-I cells\r | 577 | ||
| 9. Inhibition of human airway smooth muscle cell proliferation by vasoactive intestinal peptide\r | 587 | ||
| VIP/PACAP regulate peripheral and central neurogenesis and survival\r | 593 | ||
| VII. IMMUNE SYSTEM\r | 595 | ||
| 1. Vasoactive intestinal peptide (VIP) and related peptides : a new class of anti-inflammatory agents ?\r | 597 | ||
| 2. VIP is an inducer of interferon α/β\r | 606 | ||
| 3. VIP and immune system: Presence and gene expression in lymphocytes\r | 617 | ||
| 4. VIP binding sites sensitive to guanine nucleotides in rat peritoneal macrophage membranes: Molecular identification by convalent cross-linking\r | 624 | ||
| 5. Opposite effects of VIP on lymphocyte and macrophage functions | 635 | ||
| INDEX AND ADDRESS OF CONTRIBUTORS | 641 | ||
| SUBJECT INDEX\r | 647 |